Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

Table 4 Univariate and multivariate analysis by subgroup for overall survival

	Univariate analysis				Multivariate analysis
	HR	95%CI		P vaule	HR	95%CI		P vaule
Tumor location				< 10-4				< 10-4
CR	Ref				Ref
Pancréas	6.362	2.963	13.66		5.816	2.47	13.693
Metastatic sites				0.0634				0.9874
0-1	Ref				Ref
≥ 2	0.555	0.298	1.034		1.006	0.498	2.032
Age				0.5721				0.7614
< 75	Ref				Ref
≥ 75	1.184	0.659	2.124		1.096	0.607	1.976
Age				0.5365				0.274
< 80	Ref				Ref
≥ 80	1.277	0.588	2.774		1.611	0.686	3.786
Sexe				0.1178				0.4136
Male	Ref				Ref
Female	0.464	0.177	1.215		0.634	0.212	1.891
Comorbidities				0.0899				0.8701
No	Ref				Ref
Yes	1.787	0.914	3.495		1.066	0.494	2.301
Initial autonomy				0.7372
No	Ref
Yes	1.277	0.306	5.336
Charlson comorbidities index				0.7507
< 10	Ref
≥ 10	1.101	0.608	1.992
ECOG performance status				0.6426
0-1	Ref
≥ 2	0.833	0.385	1.802
Number of usual drugs				0.6116
< 4	Ref
≥ 4	1.169	0.64	2.132